1. Canada Stocks

  2. •

    Healthcare

  3. •

    Medical - Pharmaceuticals
InNexus Biotechnology, Inc.

InNexus Biotechnology, Inc.

IXSBF
InNexus Biotechnology, Inc.US flagOther OTC
0.00
USD
- -
- -
12,627.00Market Cap
InNexus Biotechnology, Inc.
IXSBF
(Other OTC)

Recent

price

0.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
TTM
FRC
0.01
0.02
- -
- -
0.02
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
-0.02
-0.08
-0.08
-0.06
-0.06
-0.1
-0.12
-0.12
-0.11
-0.11
-0.07
-0.03
Basic EPS, GAAP
-0.02
-0.07
-0.07
-0.09
-0.08
-0.08
-0.11
-0.07
-0.17
-0.05
-0.02
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-0.1
-0.18
-0.23
-0.18
-0.15
-0.21
-0.3
-0.29
-0.33
-0.35
-0.34
-0.24
Book Value per Share
0.16
0.09
-0.18
-0.02
0.02
-0.02
0.01
0.11
0.08
-0.06
-0.08
-0.06
Tangible Book Value per Share
4
4
4
8
15
21
25
44
55
75
96
146
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
-185.6
-436.9
-1,472.16
- -
-345.03
-50,574.91
-5,758.17
-37,785.35
-565,567.33
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
1
- -
1
1
Depreciation Expense
- -
- -
- -
- -
-1
-2
-3
-5
-6
-8
-7
-4
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-351.3
-473.03
-1,945.28
- -
-345.6
-49,489.11
-6,326.44
-33,861.53
-582,934.85
- -
- -
- -
Profit Margin (%)
1
- -
-1
- -
- -
- -
- -
5
2
-4
-9
-9
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
3
- -
- -
LT Debt
1
- -
-1
- -
1
1
1
5
5
-2
-5
-6
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'11
Dec'11
Mar'11
ST Debt
6
6
6
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
138
163
163
Market Capitalization
1
5
6

Working Capital

FRC

•

in mil. unless spec.
Sep'11
Dec'11
Mar'11
Total Current Assets
- -
- -
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
9
9
9
Payables & Accruals
3
3
3
ST Debt
6
6
6
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
9.54%
93.42%
167.36%
Free Cash Flow
76.21%
35.1%
-52.89%
Net Income, GAAP
70.75%
28.9%
-16.57%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2009
- -
- -
- -
- -
- -
2010
- -
- -
- -
- -
- -
2011
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2009
-0.03
-0.02
-0.03
- -
-0.11
2010
-0.02
-0.02
-0.02
- -
-0.07
2011
-0.01
-0.01
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2009
- -
- -
- -
- -
- -
2010
- -
- -
- -
- -
- -
2011
- -
- -
- -
- -
- -
Similar Companies
Paion AG (0NF3.L)
NIHON CHOUZAI Co.,Ltd. (3341.T)
Al-Razi Medical Co. (9572.SR)
Vista Pharmaceuticals Limited (VISTAPH.BO)
Ohki Healthcare Holdings Co.,Ltd. (3417.T)
Organon Pharma Indonesia PT (SCPI.JK)
Business
InNexus Biotechnology, Inc. InNexus Biotechnology, Inc. (IXSBF), founded in 2001 and headquartered in Vancouver, British Columbia, Canada, with principal management offices formerly in Chandler, Arizona, United States, operates as a development-stage biotechnology company focused on enhancing monoclonal antibodies through its proprietary Dynamic Cross Linking (DXL) technology. The company develops DXL-modified SuperAntibodies, including DXL625 targeting CD20 for the prospective treatment of non-Hodgkin's lymphoma and DXL702 targeting HER2/neu for breast cancer, both in preclinical stages; these antibodies feature autophilic peptides that improve binding affinity, potency for cancer therapy, and signal strength for diagnostics compared to unmodified versions. InNexus Biotechnology targets the oncology sector with products aimed at pharmaceutical and biotechnology partners for therapeutic and diagnostic applications across North America. The company delisted from the TSX Venture Exchange after voluntarily deregistering with the U.S. SEC in December 2009 via Form 15-F, maintaining a minimal operational footprint with zero employees reported as of 2012 and no significant recent partnerships, acquisitions, funding rounds, or product advancements disclosed in the past 1-2 years.